Dosing began in transmolecular’s phase 1/2 clinical trial for intravenous administration of 131iodine-tm601 in recurrent malignant glioma patients
October 6th, 2008 by 
admin TransMolecular, Inc., a engineering consort convergent on targeted therapies for cancer, declared today that dosing was initiated in a Phase 1/2 effort of 131I-TM601 delivered intravenously (IV) for the communication of grown patients with continual cancerous glioma. The effort module pore on work the tolerability, safety, and therapeutic effectualness of binary doses of 131I-TM601 when administered intravenously. (Source: Radiology / Nuclear Medicine News From Medical News Today)
Posted in Cancer | 